This satellite symposium took place on 22^nd June 2017 as part of the 22^nd European Hematology Association (EHA) Congress in Madrid, Spain

Chairperson: Michele Baccarani¹
Co-chair: Eduardo Olavarria²
Speakers: Hugues de Lavallade,³ Delphine Rea,⁴ Giovanni Martinelli¹

1. University of Bologna, Bologna, Italy
2. Imperial College London, London, UK
3. King’s College Hospital, London, UK
4. Saint-Louis Hospital, Paris, France

Disclosure: Prof Michele Baccarani received honoraria from ARIAD*/Incyte, Bristol-Myers Squibb, Novartis, and Pfizer. Dr Eduardo Olavarria has declared no conflicts of interest. Dr Hugues de Lavallade received honoraria from Bristol-Myers Squibb, Novartis, and Pfizer, and received research grant support from ARIAD*/Incyte and Bristol-Myers Squibb. Dr Delphine Rea received honoraria from ARIAD*/Incyte, Bristol-Myers Squibb, Novartis, and Pfizer. Dr Giovanni Martinelli received research support from Novartis, Bristol-Myers Squibb, Amgen, Pfizer, Genzyme, Celgene, Roche, Incyte, ARIAD*, Jansen, Cell Play, European Commission (EC) Harmony, EC Innovative Medicines Initiative 2, Fondazione del Monte di Ravenna e Bologna, CarisBo, AIRC, and AIL, and received honoraria from Novartis, Bristol-Myers Squibb, Amgen, Pfizer, AIRC, AIL, Genzyme, Celgene, ARIAD*, and Roche, and took part in speaker bureaux sponsored by Novartis, Bristol-Myers Squibb, Amgen, Pfizer, AIRC, AIL, Genzyme, Celgene, ARIAD*, and Roche. He has received honoraria from Novartis, Bristol-Myers Squibb, Amgen, Pfizer, AIRC, AIL, Genzyme, Celgene, ARIAD*, GlaxoSmithKline, Takeda, and Millennium.
*Now acquired by Takeda.
Acknowledgements: Writing assistance was provided by Sarah Etheridge, ApotheCom, London, UK.
Support: The publication of this article was funded by Incyte Biosciences International. The views and opinions expressed are those of the authors and not necessarily those of Incyte Biosciences International.
Citation: EMJ Hematol. 2017;5[1]:53-61.

Meeting Summary

This symposium was dedicated to discussing BCR-ABL-positive chronic myeloid leukaemia (CML) and Philadelphia-positive acute lymphoblastic leukaemia (Ph+ALL). Prof Baccarani opened the symposium, highlighting the recent improvements in survival in patients with BCR-ABL-positive CML and Ph+ALL. Dr de Lavallade discussed the role of mutational analyses as part of molecular monitoring, including the use of next-generation sequencing (NGS) to assess BCR-ABL mutation status and to detect low-frequency mutations. Dr Rea reviewed treatment options for CML with tyrosine kinase inhibitors (TKI) in the second and third-line treatment settings. The session concluded with Dr Martinelli presenting mutational burden in Ph+ALL patients and treatment options for these patients, in particular, with ponatinib, emphasising the importance of early treatment initiation.

This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

The post Patients in Focus: What’s Relevant for Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia? appeared first on European Medical Journal.